Erratum to: Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer

Affiliations

• ¹ University of Arizona Cancer Center, Tucson, AZ, USA. Alison.Stopeck@stonybrookmedicine.edu.
• ² Institut Gustave Roussy, University of Paris Sud, Villejuif, France.
• ³ Centre Hospitalier Universitaire Brugmann, Université Libre de Bruxelles, Brussels, Belgium.
• ⁴ Cancer Research UK Experimental Cancer Medicine Centres, St James's University Hospital, Leeds, UK.
• ⁵ Weston Park Hospital, University of Sheffield, Sheffield, UK.
• ⁶ Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
• ⁷ Center for Comprehensive Gynecology Clinic, Mannheim, Germany.
• ⁸ National Cancer Center Hospital, Tokyo, Japan.
• ⁹ Instituto de Investigación Sanitaria General Gregorio Marañón, Universidad Complutense, Madrid, Spain.
• ¹⁰ Tom Baker Cancer Centre, Calgary, AB, Canada.
• ¹¹ Cross Cancer Institute, Edmonton, AB, Canada.
• ¹² Carolina Urologic Research Center, Myrtle Beach, SC, USA.
• ¹³ Lancaster Urology, Lancaster, PA, USA.
• ¹⁴ Urology Associates, Christchurch, New Zealand.
• ¹⁵ The Urology Center of Colorado, Denver, CO, USA.
• ¹⁶ Sarah Cannon Research Institute, Nashville, TN, USA.
• ¹⁷ Amgen Inc., Thousand Oaks, CA, USA.